Teva “Cautiously Optimistic” On Copaxone Despite Generic
This article was originally published in The Pink Sheet Daily
Executive Summary
The U.S. market share for Sandoz/Momenta’s generic version of Copaxone is under 5% of the total glatiramer market, Teva said during its second quarter sales and earnings call.